Patents by Inventor Kristiina Nyyssonen

Kristiina Nyyssonen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA molecule encoding a variant alpha-2B-adrenoaceptor protein and uses thereof
    Publication number: 20040152637
    Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to the variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr;2B-adrenoceptor protein. This invention also relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to the mammal. This invention further relates to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor protein or the variant &agr;2B-adrenoceptor protein.
    Type: Application
    Filed: March 26, 2004
    Publication date: August 5, 2004
    Applicant: Oy Juvantia Pharma Ltd.
    Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssonen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen
  • DNA molecule encoding a variant &agr;2B-adrenoceptor protein, and uses thereof
    Patent number: 6696556
    Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to the variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr;2B-adrenoceptor protein. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to the mammal and to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor protein or the variant &agr;2B-adrenoceptor protein.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: February 24, 2004
    Assignee: OY Juvantia Pharma Ltd.
    Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssönen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen
  • DNA molecule encoding a variant alpha2B-adrenoceptor protein, and uses thereof
    Publication number: 20010016338
    Abstract: This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr;2B-adrenoceptor protein and to said variant &agr;2B-adrenoceptor protein as well as a method for screening a subject to determine if said subject is a carrier of a variant gene that encodes said variant &agr;2B-adrenoceptor. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, said method comprising the step of administering a selective &agr;2B-adrenoceptor antagonist to said mammal and to transgenic animals comprising a human DNA molecule encoding human &agr;2B-adrenoceptor or said variant &agr;2B-adrenoceptor.
    Type: Application
    Filed: April 5, 2001
    Publication date: August 23, 2001
    Applicant: OY Juvantia Pharma Ltd.
    Inventors: Amir Snapir, Paula Heinonen, Pia Alhopuro, Matti Karvonen, Markku Koulu, Ullamari Pesonen, Mika Scheinin, Jukka T. Salonen, Tomi-Pekka Tuomainen, Timo A. Lakka, Kristiina Nyyssonen, Riitta Salonen, Jussi Kauhanen, Veli-Pekka Valkonen